Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials.

@article{Galdy2016SystemicTB,
  title={Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials.},
  author={Salvatore Galdy and Chiara Alessandra Cella and Francesca R. Spada and Sabina Murgioni and Anna Maria Frezza and Simona Paola Ravenda and Maria Giulia Zampino and Nicola Fazio},
  journal={Critical reviews in oncology/hematology},
  year={2016},
  volume={99},
  pages={1-12}
}
Following progression on first-line platinum and fluoropyrimidine-based chemotherapy, prognosis for advanced gastric cancer patients is extremely poor. Thus, new and effective treatments are required. Based on positive results of recent randomized controlled trials, second-line monochemotherapies with either irinotecan or taxanes confer a median overall survival of approximately 5 months in gastro-esophageal and gastric adenocarcinoma. Combination of weekly paclitaxel and ramucirumab, a novel… CONTINUE READING